NCT03350828 (CHEC-SC) is a clinical trial in Cystic Fibrosis, sponsored by Nicole Hamblett.

Who is sponsoring NCT03350828?

NCT03350828 is sponsored by Nicole Hamblett.

What condition does NCT03350828 study?

NCT03350828 studies Cystic Fibrosis.

Is NCT03350828 still recruiting?

NCT03350828 is currently active, enrolled. Last updated 10 October 2025.

Last reviewed 2025-10-10 · How we verify

NCT03350828: CHEC-SC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

Active, enrolled Last updated 10 October 2025

What this trial tests

trial in Cystic Fibrosis in 5,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 January 2018

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Nicole Hamblett
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	15 January 2018
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	52 locations across United States

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Nicole Hamblett

Who can join

4 Months and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.
Nichols DP, Donaldson SH, Frederick CA, Freedman SD, et al · · 2021 · cited 68× · PMID 33619012 · DOI 10.1016/j.jcf.2021.02.003
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.
Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, et al · · 2024 · cited 18× · PMID 38360461 · DOI 10.1016/j.jcf.2024.02.001
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, et al · · 2021 · cited 16× · PMID 33573995 · DOI 10.1016/j.jcf.2021.01.011
Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.
Mayer-Hamblett N, Zemanick ET, Odem-Davis K, VanDevanter D, et al · · 2023 · cited 7× · PMID 35871974 · DOI 10.1016/j.jcf.2022.07.008
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
VanDevanter DR, Zemanick ET, Konstan MW, Ren CL, et al · · 2023 · cited 4× · PMID 37100705 · DOI 10.1016/j.jcf.2023.04.007
Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis.
Chalamalla AR, Baker E, Ryan KJ, Dowell A, et al · · 2026 · PMID 41713946 · DOI 10.1183/13993003.01594-2025

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Nicole Hamblett trials

Trials by the same sponsor.

NCT06504589 — A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators · recruiting
NCT04613128 — The PROMISE Pediatric Study 6 to 11 Years Old · active not recruiting
NCT06350474 — Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study · NA · completed
NCT06350461 — Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study · NA · completed
NCT04378153 — Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03350828 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nicole Hamblett
Last refreshed: 10 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03350828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing